Why the study?
Does long-term therapy with piroximone improve resting hemodynamics and exercise capacity in patients with congestive heart failure?
Population
10 patients with congestive heart failure
Design
Case_series
Follow-up
12 weeks
Authors
Loading...
Piroximone offers no support for improving exercise capacity in heart failure; case-report data leave open randomized safety and efficacy trials.
Does long-term therapy with piroximone improve resting hemodynamics and exercise capacity in patients with congestive heart failure?
Long-term therapy with oral piroximone in heart failure patients does not improve exercise capacity and is associated with serious adverse effects including ventricular arrhythmias and death.
Nemanich et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: